Lenvatinib and Depth of Response in Advanced uHCC: Insights From REFLECT

Opinion
Video

An expert discusses how recent analyses from the REFLECT trial in unresectable hepatocellular carcinoma (uHCC) demonstrate that both achieving objective response and greater depth of response correlate with improved survival outcomes. The depth of response serves as a potentially valuable early biomarker for prognosis and treatment decisions, with deeper responses associated with better overall survival among responders.

Video content above is prompted by the following:

  • What role do the overall response and depth of response play in guiding treatment decisions for advanced uHCC?
  • Review recent evidence from REFLECT looking at characterization of tumor response.
  • Please discuss the clinical implications from the best overall response, depth of response, and overall survival among responders’ data.
  • What are your thoughts on looking at the depth of response as a marker for clinical outcomes?

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
3 experts are featured in this series.
1 expert in this video
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
1 expert in this video
Related Content
FDA Grants Breakthrough Designation for EvoLiver in HCC

FDA Grants Breakthrough Designation for EvoLiver in HCC

Jordyn Sava
April 24th 2025
Article

EvoLiver, a blood test that detects early-stage liver cancer with high accuracy, has gained breakthrough device designation from the FDA.

Read More

Tailoring Treatments to Better Outcomes in Liver Cancer

Tailoring Treatments to Better Outcomes in Liver Cancer

Jordyn Sava;Susanne G. Warner, MD
October 13th 2023
Podcast

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Listen

First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial

First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial

Jordyn Sava
March 3rd 2025
Article

A global, randomized, phase 1b/2 trial is evaluating IO-108 in patients with metastatic and/or unresectable hepatocellular carcinoma.

Read More

FDA Fast Tracks Amezalpat for HCC Treatment

FDA Fast Tracks Amezalpat for HCC Treatment

Jordyn Sava
February 11th 2025
Article

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Read More

Nivolumab Plus Ipilimumab Improves OS and Response in Frontline uHCC

Nivolumab Plus Ipilimumab Improves OS and Response in Frontline uHCC

Jordyn Sava
January 24th 2025
Article

The CheckMate 9DW study demonstrated the efficacy and manageable safety of first-line nivolumab plus ipilimumab in patients with unresectable hepatocellular carcinoma.

Read More

TACE Plus Camrelizumab and Rivoceranib Boosts PFS in Unresectable HCC

TACE Plus Camrelizumab and Rivoceranib Boosts PFS in Unresectable HCC

Russ Conroy
January 24th 2025
Article

TACE with camrelizumab and rivoceranib significantly improves PFS in unresectable HCC, per phase 2 CARES-005 study results.

Read More

OSZAR »